A combined therapy comprising HER2 and EGFR inhibitors and HSP90 inhibitors showed improved therapeutic efficacy and the possibility of overcoming resistance in some cancers, but showed a limited effect in EGFR-mutated non-small cell lung cancer (NSCLC). This evidence concerns the gene HSP90AB1 and cancer.